Barry Rosenblum, MD
Otolaryngology · Saint Louis, MONPI 1750318341
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,652 of the $4,372 with a category attached, or 60.7%. 14 manufacturers reported payments, led by Stryker at 50.2% of the total. Reporting peaked in 2019 at $2,416 and has fallen 91.6% since, to $203 in 2025.
Across 58 payments — averaging $75.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$2K
- Acclarent, Inc$994
- Intersect ENT, Inc.$641
- Integra Lifesciences Corporation$295
- KARL Storz Endoscopy-america$53
- Smith+Nephew$38
- plus $157 from 8 others
What the payments were for
- Travel & lodging$1,69539%
- Food & beverage$2,65261%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 14 | $2,194 |
| Acclarent, Inc | 12 | $994 |
| Intersect ENT, Inc. | 11 | $641 |
| Integra Lifesciences Corporation | 7 | $295 |
| KARL Storz Endoscopy-america | 2 | $53 |
| Smith+Nephew | 2 | $38 |
| Davol Inc. | 1 | $29 |
| Johnson & Johnson | 2 | $29 |
| Amgen | 2 | $27 |
| GSK | 1 | $16 |
| Covidien LP | 1 | $15 |
| Novartis | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,372 in reported general payments places this provider in the 85th percentile of 210 otolaryngology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 14 | $1,546 |
| Cefdinir | 71 | $1,461 |
| Azelastine Hcl | 20 | $687 |
| Methylprednisolone | 65 | $445 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 27 | $233 |
| Montelukast Sodium | 25 | $120 |
| Mometasone Furoate | 16 | $93 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Saint Louis
- Ryan JacksonSaint Louis$284K
- Ravindra UppaluriSaint Louis$168K
- John SchneiderSaint Louis$74K
- Amit WaliaSaint Louis$21K
- Bharat PanugantiSaint Louis$19K
- Cristine Klatt-CromwellSaint Louis$13K
- Lauren RolandSaint Louis$11K
- James HartmanSaint Louis$7K
- Robert ObertSaint Louis$7K
- Arya NaminSaint Louis$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.